Correlation Between Passage Bio and Ambrx Biopharma

Can any of the company-specific risk be diversified away by investing in both Passage Bio and Ambrx Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Passage Bio and Ambrx Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Passage Bio and Ambrx Biopharma American, you can compare the effects of market volatilities on Passage Bio and Ambrx Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Passage Bio with a short position of Ambrx Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Passage Bio and Ambrx Biopharma.

Diversification Opportunities for Passage Bio and Ambrx Biopharma

0.33

Correlation Coefficient

Passage Bio  Ambrx Biopharma

Weak diversification

The 3 months correlation between Passage and Ambrx is 0.33. Overlapping area represents the amount of risk that can be diversified away by holding Passage Bio and Ambrx Biopharma American in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ambrx Biopharma American and Passage Bio is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Passage Bio are associated (or correlated) with Ambrx Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ambrx Biopharma American has no effect on the direction of Passage Bio i.e., Passage Bio and Ambrx Biopharma go up and down completely randomly.

Pair Corralation between Passage Bio and Ambrx Biopharma

Given the investment horizon of 90 days Passage Bio is expected to generate 6.84 times less return on investment than Ambrx Biopharma. In addition to that, Passage Bio is 1.62 times more volatile than Ambrx Biopharma American. It trades about 0.02 of its total potential returns per unit of risk. Ambrx Biopharma American is currently generating about 0.18 per unit of volatility. If you would invest  1,456  in Ambrx Biopharma American on September 30, 2024 and sell it today you would earn a total of  117.00  from holding Ambrx Biopharma American or generate 8.04% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	3.22%
Values	Daily Returns

Passage Bio  vs.  Ambrx Biopharma American

Passage Bio

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Passage Bio are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak basic indicators, Passage Bio reported solid returns over the last few months and may actually be approaching a breakup point.

Ambrx Biopharma American

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Ambrx Biopharma American has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Ambrx Biopharma is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors.

Pair Trading with Passage Bio and Ambrx Biopharma

The main advantage of trading using opposite Passage Bio and Ambrx Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Passage Bio position performs unexpectedly, Ambrx Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ambrx Biopharma will offset losses from the drop in Ambrx Biopharma's long position.

The idea behind Passage Bio and Ambrx Biopharma American pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.